The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study

Roviello G.

•

•

Sobhani N.

2019

journal article

Periodico

TRANSLATIONAL CANCER RESEARCH

Abstract

N/A

DOI

10.21037/tcr.2018.10.17

WOS

WOS:000462575500004

Archivio

https://hdl.handle.net/11368/3053138

info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85065960111

https://tcr.amegroups.org/article/view/24832/20387

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797650/

Diritti

open access

license:creative commons

license uri:http://creativecommons.org/licenses/by-nc-nd/4.0/

FVG url

https://arts.units.it/bitstream/11368/3053138/1/tcr-08-S2-S94.pdf

Soggetti